Karuna Therapeutics, Inc.
KRTXDelisted Mar 18, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001771917
Karuna Therapeutics, Inc. was delisted on Mar 18, 2024; its insiders filed their last Form 4 on Mar 18, 2024; 328 institutions reported holding it in 13F filings for Q4 2023, worth $12.0B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 328
- Q4 2023, +73 vs. previous quarter
- 13F value
- $12.0B
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Superinvestors holding KRTX, Q4 2023
No superinvestor reported holding KRTX at the end of Q4 2023.
Latest insider trades
Open-market purchases and sales by Karuna Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2024 (view filing) | Mar 8 | 3 days | Brannan Stephen K.Chief Medical Officer | SSale | −5.00K | $318.34 | −$1.59M | −10.5%42.6K after | 2 lots10b5-1 |
| Feb 12, 2024 (view filing) | Feb 8 | 4 days | Brannan Stephen K.Chief Medical Officer | SSale | −5.00K | $316.13 | −$1.58M | −10.8%41.1K after | 2 lots10b5-1 |
| Jan 9, 2024 (view filing) | Jan 8 | 1 day | Brannan Stephen K.Chief Medical Officer | SSale | −15.0K | $316.81 | −$4.75M | −28.0%38.6K after | 10b5-1 |
| Dec 12, 2023 (view filing) | Dec 8 | 4 days | Brannan Stephen K.Chief Medical Officer | SSale | −10.0K | $202.37 | −$2.02M | −21.7%36.1K after | 5 lots10b5-1 |
| Nov 13, 2023 (view filing) | Nov 8 | 5 days | Brannan Stephen K.Chief Medical Officer | SSale | −5.00K | $177.85 | −$889.3K | −12.9%33.6K after | 5 lots10b5-1 |
| Oct 10, 2023 (view filing) | Oct 9 | 1 day | Brannan Stephen K.Chief Medical Officer | SSale | −5.00K | $173.24 | −$866.2K | −13.8%31.1K after | 2 lots10b5-1 |
| Sep 11, 2023 (view filing) | Sep 8 | 3 days | Brannan Stephen K.Chief Medical Officer | SSale | −5.00K | $184.04 | −$920.2K | −14.9%28.6K after | 4 lots10b5-1 |
| Sep 5, 2023 (view filing) | Sep 1 | 4 days | Jonas Jeffrey MDirector | SSale | −13.8K | $187.93 | −$2.60M | −93.3%990 after | 4 lots10b5-1 |
| Aug 24, 2023 (view filing) | Aug 22 | 2 days | Ignelzi Troy A.Chief Financial Officer | SSale | −1.50K | $175.12 | −$262.7K | −4.7%30.5K after | 4 lots10b5-1 |
| Aug 10, 2023 (view filing) | Aug 8 | 2 days | Brannan Stephen K.Chief Medical Officer | SSale | −5.00K | $180.40 | −$902.0K | −16.1%26.1K after | 3 lots10b5-1 |
Top 10 13F holders, Q4 2023
The largest institutional positions in Karuna Therapeutics, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Capital International Investors | 4,227,102 | $1.34B | 0.30% | +236,491+5.9% | Added |
| Vanguard Group Inc | 3,224,786 | $1.02B | 0.02% | +21,201+0.7% | Added |
| FMR LLC | 2,865,994 | $907.1M | 0.07% | −2,784,173−49.3% | Reduced |
| T. Rowe Price Investment Management, Inc. | 2,709,629 | $857.6M | 0.56% | −32,828−1.2% | Reduced |
| BlackRock Inc. | 2,015,374 | $637.9M | 0.02% | +52,457+2.7% | Added |
| Price T Rowe Associates Inc | 1,961,587 | $620.9M | 0.08% | −773,251−28.3% | Reduced |
| Sofinnova Investments, Inc. | 1,381,149 | $437.1M | 24.49% | 00.0% | Unchanged |
| Wellington Management Group LLP | 1,134,046 | $358.9M | 0.07% | −151,462−11.8% | Reduced |
| Pentwater Capital Management LP | 1,066,200 | $337.5M | 6.34% | +1,037,700+3,641.1% | Added |
| General Atlantic LLC | 986,710 | $312.3M | 4.48% | 00.0% | Unchanged |